Evaluation for Pharmaceutical Characteristics of Nalfurafine Orally Disintegrating Film Agent-Reference-Cited by-同舟云学术

Evaluation for Pharmaceutical Characteristics of Nalfurafine Orally Disintegrating Film Agent

Published:2022-01-10 Issue:1 Volume:48 Page:53-58
ISSN:1346-342X
Container-title:Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)
language:en
Short-container-title:Jpn. J. Pharm. Health Care Sci.

Author:

Oda Kazutaka¹,Matsushita Keisuke²,Unoki Junpei²,Ozeki Kazuya²,Tanaka Hitomi²,Yamaoka Michiko²,Gunda Nao²,Shimomura Yumi²,Nishimura Yuka²,Yamaguchi Ayami²,Ito Yuki²,Nishigaki Aina²,Baba Yusuke²,Michiwaki Natsumi²,Uchino Shota²,Kurogi Kayo²,Horikawa Mai²,Matsumoto Naoya²,Yonemaru Kou²,Arakaki Hitomi²,Katsume Taiki²,Matsuyama Kaho²,Jono Hirofumi²,Saito Hideyuki²

Affiliation:

1. Department of Pharmacy, Kumamoto University Hospital

2. Department of Clinical Pharmaceutical Sciences, Graduate School of Pharmaceutical Sciences, Kumamoto University

Publisher

Japanese Society of Pharmaceutical Health Care and Sciences

Subject

General Earth and Planetary Sciences,General Environmental Science

Link

https://www.jstage.jst.go.jp/article/jjphcs/48/1/48_53/_pdf

Reference11 articles.

1. 1）佐藤貴浩, 横関博雄, 室田浩之, 戸倉新樹, 椛島健治, 高森建二, 塩原哲夫, 森田栄伸, 相場節也, 青山裕美, 端本宇志, 片山一朗, 皮膚瘙痒症診療ガイドライン2020, 日本皮膚科学会雑誌, 2020, 130, 1589-1606.

2. 2）Weisshaar E, Dalgard F, Epidemiology of itch: adding to the burden of skin morbidity, Acta Derm Venereol, 2009, 89, 339-350.

3. 3）Raslan HM, Ezzat WM, Abd El Hamid MF, Emam H, Amre KS, Skin manifestations of chronic hepatitis C virus infection in Cairo, Egypt, East Mediterr Health J, 2009, 15, 692-700.

4. 4）Nakamoto H, Oh T, Shimamura M, Iida E, Moritake S, Nalfurafine hydrochloride for refractory pruritus in peritoneal dialysis patients: a phase III, multi-institutional, non-controlled, open-label trial, Renal Replacement Therapy, 2017, 3, 51. doi:10.1186/s41100-017-0133-8.

5. 5）Kumada H, Miyakawa H, Muramatsu T, Ando N, Oh T, Takamori K, Nakamoto H, Efficacy of nalfurafine hydrochloride in patients with chronic liver disease with refractory pruritus: A randomized, double-blind trial, Hepatol Res, 2017, 47, 972-982.